CCPP has initiated the following studies sponsored by pharmaceutical companies:

• ENGAGE, Phase 3 international multicenter study funded by the BIOGEN pharmaceutical company, to evaluate the efficacy and safety of an innovative drug called Aducanumab, aimed at the treatment of patients with early Alzheimer’s disease [study in progress]
• ADVANCE, Phase 3 international study funded by the Baxalta pharmaceutical company, to evaluate the efficacy, safety and tolerability of an infusion of subcutaneous immunoglobulins for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) [study in progress]
• CRED, a multicenter, randomized double-blind, Phase 3 international study funded by the ROCHE pharmaceutical company, to evaluate the efficacy and safety of Crenezumab in patients with mild Alzheimer’s disease (probable AD / prodromal AD) [study concluded]
• MS-COG, a multi-center study funded by the BIOGEN pharmaceutical company on healthy subjects, aimed at establishing the reference values ​​for the MS-COG cognitive assessment scale in a population overlapping that of patients with multiple sclerosis [study concluded]